Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.51 |
| ▸ | CTSA | P10619 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19898227 | 1.00 | BRD4 (0.54) | BRD4GRM4CTSACLK1CLK2 | |
| Formic Acid SCHEMBL30925240 | 0.93 | BRD4 (0.49) | BRD4GRM4CTSACLK1CLK2 | |
| SCHEMBL31224250 | 0.87 | GRM4 (0.48) | BRD4GRM4CTSACLK1CLK2 | |
| SCHEMBL8403540 | 0.86 | BRD4 (0.62) | BRD4P2RX7GAAPOLBMAPT | |
| SCHEMBL108143 | 0.81 | P2RX7 (0.62) | GRM4CTSAP2RX7GAAPOLB | |
| SCHEMBL31514785 | 0.80 | CTSA (0.54) | GRM4CTSACLK1CLK2MAPT | |
| SCHEMBL30380244 | 0.78 | KDM4E (0.68) | BRD4POLBPTGS1PTGS2 | |
| SCHEMBL10289971 | 0.78 | BRD4 (0.56) | BRD4P2RX7GAAPOLBMAPT | |
| SCHEMBL8300009 | 0.78 | P2RX7 (0.70) | BRD4CTSAP2RX7POLBMAPT | |
| SCHEMBL16987892 | 0.78 | BRD4 (0.56) | BRD4P2RX7GAAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452256-B1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2025-12-10 | — | — | EP | claimed |
| CN-122055364-A | PARP1 targeting compounds and uses thereof | 成都赜灵生物医药科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4452256-B1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2025-12-10 | — | — | EP | disclosed |
| CN-120092010-A | Polycyclic poly (ADP-ribose) polymerase selective inhibitors | 轩竹生物科技股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119487027-A | Compounds as PARP1 inhibitors | 宁波新湾科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118119629-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117447449-A | PARP1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116348115-A | Combination of antibody-drug conjugate and PARP1 selective inhibitor | 阿斯利康(英国)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3999506-A1 | PARP1 INHIBITORS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144413-A | PARP1 inhibitors | 阿斯利康(瑞典)有限公司 | 2022-03-04 | — | — | CN | disclosed |